Status:
UNKNOWN
Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)
Lead Sponsor:
IRCCS San Raffaele
Conditions:
Pancreas Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is the characterization from epidemiological, radiomics and molecular point of view of lung metastasis of patients at beginning affected by pancreatic adenocarcinoma (PDAC), whic...
Detailed Description
Radical surgical treatment of primitive PDAC, associated with adjuvant cancer treatments, is possible only in 15-20% of patients, and, to date, represents the best therapeutic strategy. Nevertheless, ...
Eligibility Criteria
Inclusion
- Cytological/histological diagnosis of pancreatic adenocarcinoma as a primary tumor and localization of adenocarcinoma compatible with pancreatic primitivity for lung metastasis;
- Previous surgical resection of the primary tumor;
- Exclusive presence of single or multiple lung metastasis at disease recurrence;
- Radical or diagnostic excision of lung metastasis;
- Informed patient consent (for currently living patients).
Exclusion
- Patients not undergoing lung resection surgery for diagnostic and/or therapeutic purposes for cardiac or respiratory functional contraindication.
- Patients with lung metastases synchronous with primary cancer. Contacts and Locations
Key Trial Info
Start Date :
May 27 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT04435067
Start Date
May 27 2020
End Date
December 31 2021
Last Update
July 16 2020
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
IRCCS San Raffaele Diagnostic Radiology Unit
Milan, Italy, 20132
2
IRCCS San Raffaele Medical Oncology Unit
Milan, Italy, 20132
3
IRCCS San Raffaele Pathological Anatomy Unit
Milan, Italy, 20132
4
IRCCS San Raffaele Thoracic Surgery Unit
Milan, Italy, 20132